|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o BioAlliance Pharma, of Paris, reported that one of its lead products, doxorubicin Transdrug, was granted orphan drug status for the treatment of hepatocellular carcinoma by the FDA. The product is completing Phase I/II testing in the EU for treatment of hepatocellular carcinoma.
o BioFactura Inc., of Rockville, Md., received an investment from the Maryland Technology Development Corp. to support collaborative efforts it has with USAMRIID at Fort Detrick, Md., developing therapeutics in poxviruses. BioFactura offers process development and manufacturing services to customers and partners seeking therapeutics, vaccines and diagnostics to the commercial markets.
...